Anti-gout drugs are also known as anti-hyperuricemic drugs. Gout is rare in children. People who have had an organ transplant or kidney disease, or men aged between 40 and 50 are more prone to gout. Anti-gout drugs correct the under excretion or overproduction of uric acid. These can effectively control hyperuricemia for a long term that is caused due to formation of uric acid from purines. The choice of uricosuric medicines or xanthine oxidase inhibitors is based on presence of tophi, history of renal calculi, patient’s age, renal function, and the level of urinary uric acid excretion. Gout is formed due to medical conditions including urinary tract stones, sweet's syndrome, sarcoidosis, reactive perforating collangenosis, pseudo gout prophylaxis, mania, linear IgA disease, leishmaniasis, hyperuricemia secondary to chemotherapy, high risk percutaneous trans-luminal angioplasty, heart failure, and gouty arthritis. Gout is also formed due to indications such as fibromatosis, familial Mediterranean fever, constipation, chronic cardiothoracic surgery, calcium oxalate calculi with hyper-uricosuria, biliary cirrhosis, Behcet's disease, aphthous stomatitis, amyloidosis, and adjunct to antibiotic therapy.
Gout is the most common form of arthritis, a joint inflammation. It is also known as acute attack. Symptoms of gout start within 12 hours to 24 hours at the affected joint. The symptoms include swelling and severe pain at the affected area of joint. Most often ankles and feet are affected by gout and one joint is affected at a time. The most common sites of gout include the joints in the big toe. The drugs available for treatment can be divided based on type of gout: acute gout, gout prophylaxis, gouty arthritis, pseudo gout, and pseudo gout prophylaxis. Acute gout is also known as gout flare. Acute gout is usually caused at one bone joint; however, there are exceptions that involve more joints. Acute gout causes disabling and painful inflammatory arthritis. Acute gout is caused due to high levels of uric acid that forms crystals and accumulate around the joints that cause inflammation and swelling. Gout prophylaxis is a preventive measure taken to avoid the reoccurring acute attack of gout. Gouty arthritis is an attack that is intensively painful caused due to the deposition of crystals of uric acid that occur in the joint fluid. Pseudo gout is a joint indication that is caused due to attacks of arthritis because of formation of crystals in the joints. The crystals in the pseudo gout are not formed of uric acid as in the case of true gout, but are caused due to salt called calcium pyrophosphate di-hydrate. Pseudo gout prophylaxis is a preventive measure taken to avoid the formation of crystals of calcium pyrophosphate di-hydrate in the joints that cause arthritis attacks.
Increase in prevalence of gout across the world drives the global anti-gout drugs market. According to the Arthritis Foundation, 8.3 million people aged 20 or older, three fourth of these are men, are affected by gout. Rise in kidney diseases and organ transplant surgeries drive demand for anti-gout drugs across the globe. Surge in consumption of alcohol among the population across the world fuels the growth of the market.
The global anti-gout drugs market can be segmented based on disease type, dosage form, distribution channel, and region. In terms of disease type, the market can be categorized into acute gout, gout prophylaxis, gouty arthritis, pseudo gout, and pseudo gout prophylaxis. Based on dosage form, the global anti-gout drugs market can be bifurcated into oral and parental. Oral dosage form can be divided into tablets and capsules. In terms of distribution channel, the market can be classified into online pharmacies, retail pharmacies, and hospital pharmacies.
Geographically, the global anti-gout drugs market can be classified into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America held the largest market share in 2016, followed by Europe, due to increase in research and development on anti-gout drugs in the regions. The market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period due to increase in government initiatives for the health care sector. The anti-gout drugs market in Latin America and Middle East & Africa is projected to grow at a moderate pace during the forecast period.
Key players in the global anti-gout drugs market include Pfizer, Inc., Casper Pharma, AR Scientific, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.